BACKGROUND Current pharmacologic treatment of the neonatal abstinence syndrome with morphine is associated with a lengthy duration of therapy and hospitalization. Buprenorphine may be more effective than morphine for this indication. METHODS In this single-site, double-blind, double-dummy clinical trial, we randomly assigned 63 term infants (≥37 weeks of gestation) who had been exposed to opi...

Buprenorphine, a new powerful analgesic agent, was used to treat chest pain in patients with suspected myocardial infarction. Initial studies showed no significant changes in systemic or pulmonary artery blood pressure or in heart rate after intravenous buprenorphine. Sublingual buprenorphine also appeared effective in relieving pain, but its onset of action was considerably delayed compared wi...

I n t e r v e n t i o n 110 patients were allocated to daily, officebased combination treatment with 16-mg sublingual buprenorphine plus 4-mg naloxone for 4 weeks; buprenorphine was administered alone on day 1 (8 mg) and day 2 (16 mg) to minimize the risk for naloxoneinduced opiate withdrawal. 106 patients were allocated to buprenorphine alone; 8 mg on day 1, and 16 mg thereafter. 110 patients ...

Intervention 12 weeks of buprenorphine or placebo as interim treatment while participants awaited drug-assisted rehabilitation. Sublingual tablets were given under supervision each weekday, with a double dose on Saturdays and no dose on Sundays. Take-home doses were prohibited. On day 1, both groups received 4mg buprenorphine. Over approximately the next week, the intervention group’s dose incr...

BACKGROUND Buprenorphine is a promising alternative to methadone or levo-acetyl alpha methadol for opioid agonist maintenance treatment, and thrice-weekly dosing would facilitate its use for this purpose. METHODS After a 3-day induction, opioid-dependent patients (n = 92) were randomly assigned to daily clinic attendance and 12-weeks maintenance treatment with sublingual buprenorphine adminis...

Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003;349:949–58. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...

In early January 2022, FDA released a Drug Safety Communication surrounding dental problems following use of buccal and sublingual buprenorphine products for the treatment pain opioid disorder. The warning comes after reports problems, including tooth decay, cavities, oral infections, loss teeth, in patients using buprenorphine, regardless their history. Buprenorphine variety formulations, Subu...

Buprenorphine in sublingual formulation was recently introduced to the American market for treatment of opioid dependence. We report a series of 5 toddlers with respiratory and mental-status depression after unintentional buprenorphine exposure. Despite buprenorphine's partial agonist activity and ceiling effect on respiratory depression, all children required hospital admission and either opio...